Helicos BioSciences Strengthens Executive Management Team in Preparation for Commercial Launch

Helicos BioSciences Corporation

Helicos BioSciences Strengthens Executive Management Team in Preparation for Commercial Launch

June 19, 2007

 CAMBRIDGE, Mass., Jun 19, 2007 (BUSINESS WIRE) -- Helicos BioSciences Corporation (NASDAQ: HLCS) announced today the addition of new members to its executive management team as a key step in building a commercial organization. Chip Leveille has been appointed Vice President of Sales and Marketing and Mark Solakian has been named Vice President and General Counsel.

"Chip and Mark are proven leaders bringing years of experience and expertise to Helicos," said Stanley N. Lapidus, President and CEO of Helicos. "Their addition to the Helicos management team is another significant step as we move toward the commercialization of our technology."

Chip Leveille joins Helicos from Affymetrix where he served as Vice President in three separate capacities - Pharmaceutical Business, Core Technologies Group and Corporate Marketing. During his six years with Affymetrix, Leveille played a key role in transforming Affymetrix to a systems company. The company achieved record instrument sales and product margins during his tenure while setting the foundation for its Molecular Diagnostic business through the introduction of the first FDA 510(k) cleared microarray system. He has over 15 years of sales and marketing experience and a proven talent for building and leading global organizations.

"The Helicos technology is a significant advancement in throughput, scalability and performance," said Leveille. "I believe this technology will enable many new applications and will be a key driver in the advancement of personalized medicine."

Mark Solakian brings over 12 years of legal experience to Helicos, serving most recently as Vice President and Chief Corporate Counsel for Affymetrix, where he managed a team of attorneys responsible for all corporate legal affairs including securities laws and corporate governance matters, strategic alliances and collaborations, acquisitions and corporate finance transactions. Prior to joining Affymetrix, Solakian was an attorney at Goodwin Procter LLP in Boston. He received his AB from Harvard College and JD from Boston College Law School. While at Boston College Law School, he was Executive Editor of the Boston College Law Review.

"It is exciting to be a part of such an experienced management team," said Solakian. "It is a wonderful opportunity for me to join a corporation that has the ability to make profound contributions to our understanding of complex diseases."

About Helicos BioSciences

Helicos BioSciences Corporation is a life sciences company developing innovative genetic analysis technologies for the research, drug discovery and clinical diagnostics markets. The company has developed its proprietary True Single Molecule Sequencing technology to enable ultra-high-throughput genetic analysis based on the direct sequencing of single molecules of nucleic acids. The company's corporate headquarters are located at One Kendall Square, Building 700, Cambridge, MA 02139, and its telephone number is (617) 264-1800.

Certain statements made in this press release that are not based on historical information are forward-looking statements which are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. This press release contains express or implied forward-looking statements relating to, among other things, Helicos' expectations concerning the prospective value of Chip Leveille's and Mark Solakian's experiences and expertise to Helicos and management's plans, objectives and strategies. These statements are neither promises nor guarantees, but are subject to a variety of risks and uncertainties, many of which are beyond Helicos' control, which could cause actual results to differ materially from those contemplated in these forward-looking statements. In particular, the risks and uncertainties include, among other things, our ability to successfully complete the manufacturing process and commercialize the HeliScope system; competition; changing technology and customer requirements; our ability to operate in an emerging market; market acceptance of our technology; our ability to retain our personnel and hire additional skilled personnel; our ability to manage our rapid growth and our ability to obtain capital when desired on favorable terms. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Helicos undertakes no obligation to update or revise the information contained in this press release, whether as a result of new information, future events or circumstances or otherwise. For additional disclosure regarding these and other risks faced by Helicos, see the disclosure contained in Helicos' public filings with the Securities and Exchange Commission.

Investor Relations:
Helicos BioSciences Corporation
Louise Mawhinney, 617-264-1800
Sr. Vice President and Chief Financial Officer

or

Media Contact:
Racepoint Group
Sally Bain, 781-487-4647
sbain@racepointgroup.com